A Estimation of liver function tests and IL 6 for pregnant women with hepatitis B and C with Baghdad teaching hospital Estimation of liver function tests and IL 6 for pregnant women with hepatitis B and C
Article Sidebar
Main Article Content
Abstract
Liver inflammation is called hepatitis, which can go away on its own or get worse and turn into cirrhosis, fibrosis, or liver cancer. Liver function tests explore serious liver diseases progression and their impact, like viral hepatitis. Aspartate and ALT, are frequently elevated and discharged into the bloodstream following a hepatitis infection. The study's objective was to determine the levels of liver enzymes and IL 6 in pregnant women with hepatitis C and B virus groups at various stages of the illness. Blood samples were collected from 40 pregnant women infected with hepatitis who visited Baghdad Medical Hospital in Baghdad Governorate / Iraq for use in determining HBsAg, HCV, ALT, AST, ALP, Direct Bilirubin, and IL-6. The study result shows there are significant differences (P≤0.05) between the pregnant women with hepatitis B and C in the study samples; the number of pregnant women suffering from HBV in the studied group was 39 (65%) in comparison with the number of pregnant women suffering from HCV 21 patient (35 %). In our research, Total blood bilirubin (TSB) levels and liver enzymes were found to be significantly different (P≤0.05) between pregnant women with hepatitis B and C in this study. There were also big changes in the levels of AST. The average AST for HBV was 19.90 ± 5.77, while 26.64 ± 5.11 for HCV. No big differences were found in the ALT or ALP levels, and IL-6 levels were not significantly different between the viral types, with a negative correlation. We conclude that there are significant differences in certain biochemical parameters between pregnant women infected with hepatitis B and C. Specifically, TSB and AST levels were notably higher in HCV patients.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/
References
1. Jamal SA, Naqid IA, Hussein NR, Abdulqader SR, Nimet AA, et al. The prevalence of hepatitis B and C virus infections in the couples attending a premarital screening program in Zakho City, Kurdistan Region of Iraq. Zahedan Journal of Research in Medical Sciences. 2021;23(2):e99405. doi:10.5812/zjrms.99405.
2. Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol. 2021;45(3):101626. doi:10.1016/j.clinre.2021.101626.
3. Coppola N, De Pascalis S, Onorato L, Calò F, Sagnelli C, Sagnelli E. Hepatitis B virus and hepatitis C virus infection in healthcare workers. World J Hepatol. 2016;8(5):273-281. doi:10.4254/wjh.v8.i5.273
4. Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017;217(5):B2-B12. doi:10.1016/j.ajog.2017.07.039
5. Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J. 2012;9:186. Published 2012 Sep 6. doi:10.1186/1743-422X-9-186
6. Geta M, Yizengaw E, Getaneh Z, Getahun T. Seroprevalence of Hepatitis B Virus Infection Among Patients Attending at Addis Alem Primary Hospital, Bahir Dar, Northwest Ethiopia. Int J Gen Med. 2021;14:405-411. Published 2021 Feb 10. doi:10.2147/IJGM.S298586
7. Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol. 2021;27(28):4603-4638. doi:10.3748/wjg.v27.i28.4603
8. Wolf JM, De Carli S, Pereira VRZB, Simon D, Lunge VR. Temporal evolution and global spread of hepatitis B virus genotype G. J Viral Hepat. 2021;28(2):393-399. doi:10.1111/jvh.13431
9. Migita K, Abiru S, Maeda Y, et al. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum Immunol. 2006;67(1-2):27-32. doi:10.1016/j.humimm.2006.02.025
10. Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1(1):58-70. doi:10.3978/j.issn.2224-4778.2011.11.02
11. Zhou C, Zhang N, He TT, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2020;26(30):4479-4488. doi:10.3748/wjg.v26.i30.4479
12. SAS S. Statistical Analysis System, User’s Guide. Version SAS Inst Inc. Cary, NC: USA; 2012.
13. Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis. BMJ. 2001;322(7279):151-153. doi:10.1136/bmj.322.7279.151
14. Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol. 2014;20(40):14559-14567. doi:10.3748/wjg.v20.i40.14559
15. Lee CY, Tsai HC, Lee SS, et al. Higher rate of hepatitis events in patients with human immunodeficiency virus, hepatitis B, and hepatitis D genotype II infection: a cohort study in a medical center in southern Taiwan. J Microbiol Immunol Infect. 2015;48(1):20-27. doi:10.1016/j.jmii.2013.08.001
16. Elinav E, Ben-Dov IZ, Shapira Y, et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology. 2006;130(4):1129-1134. doi:10.1053/j.gastro.2006.01.007
17. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002;99(6):1049-1052. doi:10.1016/s0029-7844(02)02000-8
18. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol. 1991;8(3):227-232. doi:10.1055/s-2007-999384
19. Ejele OA, Ojule AC. The prevalence of hepatitis B surface antigen (HBsAg) among prospective blood donors and patients in Port Harcourt, Nigeria. Niger J Med. 2004;13(4):336-338.
20. Otegbayo JA, Fasola FA, Abja A. Prevalence of hepatitis B surface and e antigens, risk factors for viral acquisition and serum transaminase among blood donors in Ibadan, Nigeria. Trop Gastroenterol. 2003;24(4):196-197.
21. Egah DZ, Banwat EB, Audu ES, et al. Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria. East Mediterr Health J. 2007;13(4):961-966.
22. Batool A, Bano KA, Khan MU, Hussain R. Antenatal screening of women for Hepatitis B and C in an outpatient department. J Dow Univ Health Sci. 2008;2:32-35.
23. Erden S, Büyüköztürk S, Calangu S, Yilmaz G, Palanduz S, Badur S. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Med Princ Pract. 2003;12(3):184-188. doi:10.1159/000070757
24. Ahmad J, Taj AS, Rahim A, et al. Frequency of Hepatitis B and Hepatitis C in healthy blood donors of NWFP. J Postgrad Med Inst. 2004;18:343-352.
25. Ohto H, Terazama S, Sasaki N. Transmission of Hepatitis C virus from mother to infant. N Engl J Med. 1994;330:744-750. doi:10.1056/NEJM199403173301103.
26. Iannacone M, Sitia G, Ruggeri ZM, Guidotti LG. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol. 2007;46(4):719-726. doi:10.1016/j.jhep.2006.12.013.
27. Houghton M. Hepatitis C viruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia, PA: Lippincott Raven; 1996:1035-1058.
28. Ssekamatte T, Isunju JB, Mutyoba JN, et al. Predictors of Hepatitis B screening and vaccination status of young psychoactive substance users in informal settlements in Kampala, Uganda. PLoS One. 2022;17(5):e0267281. doi:10.1371/journal.pone.0267281.
29. Khalid MD, Abdullah BA. Hepatitis C virus genotypes in Iraq. Iraqi J Biotechnol. 2012;11(2):475-480.
30. Zhang L, Miao L, Han F, Dou XG. Cytokine levels in serum of patients with chronic hepatitis C and its significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011;27:301-303.
31. Ribeiro CRA, de Almeida NAA, Martinelli KG, et al. Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients. Virol J. 2021;18(1):15. Published 2021 Jan 12. doi:10.1186/s12985-021-01487-2